Insider Sale: EVP & Group Pres of $BSX Sells 56,372 Shares

EVP & Group President of $BSX, Joseph Michael Fitzgerald, sold 56,372 shares on June 4, 2025, for approximately $5.8 million, representing 24% of his holdings in that class of stock. This sale is part of a broader trend of insider selling at $BSX over the past six months, with executives and members of congress primarily selling shares, while institutional investors showed mixed activity in Q1 2025, with Franklin Resources reducing their position by 55% and JP Morgan Chase increasing theirs by 20%. Despite the insider selling, Wall Street analysts maintain a generally positive outlook on $BSX, with eight firms issuing buy ratings and a median price target of $116.

Analysis

A significant insider sale at Boston Scientific ($BSX) saw EVP & Group President Joseph Michael Fitzgerald dispose of 56,372 shares, valued at approximately $5.8 million, constituting 24.0% of his holdings in that stock class on June 4, 2025. This transaction is part of a pronounced trend of insider selling, with $BSX insiders executing 32 sales and zero purchases over the past six months; notable sales include CEO Michael F. Mahoney divesting 493,328 shares for roughly $50.3 million and CFO Daniel J. Brennan selling 99,950 shares for about $10.5 million. This consistent selling pressure from top executives contrasts with mixed signals from institutional investors in Q1 2025: while 868 institutions increased their $BSX positions, 689 reduced them. Significant reductions were seen from Franklin Resources, which cut its stake by 55.0% (9.1 million shares, ~$917 million), and DZ Bank, which decreased its holding by 20.5%. Conversely, JPMorgan Chase augmented its position by 20.1% (5.3 million shares, ~$533 million), and Two Sigma Advisers reported a substantial 456.9% increase. Congressional trading activity also shows a net selling inclination, with 4 sales versus 2 purchases in the last six months. Despite these insider sales and mixed institutional flows, which contribute to a mildly negative overall sentiment (-0.3) and a specifically slightly negative sentiment for $BSX (-0.2), Wall Street analysts maintain a strong consensus, with eight firms issuing buy-equivalent ratings and no sell ratings recently. The median analyst price target stands at $116, with recent targets ranging from $100 to $124, implying analysts anticipate further upside.

Key Decisions for Investors

• Investors should exercise caution due to the consistent and substantial insider selling by $BSX executives, including the CEO and CFO, which may indicate a perception of full valuation or internal headwinds not yet reflected in analyst ratings.
• The divergent institutional investor activity in Q1 2025, with major funds like Franklin Resources significantly reducing holdings while others like JPMorgan Chase increased theirs, warrants close monitoring of subsequent 13F filings to gauge shifts in large-scale investor conviction.
• While analyst ratings are uniformly positive with a median price target of $116, this optimism should be critically evaluated against the backdrop of persistent insider dispositions and the reported mildly negative sentiment; thorough due diligence on the company's fundamental growth drivers and competitive positioning is advised.